Tarsus Pharmaceuticals annual net debt
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Net Debt Growth & History (TARS)
Tarsus Pharmaceuticals's net debt was −$100.6M for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$100.6M | −$78.2M | — |
| 2024 | 2024-12-31 | −$22.4M | $170.8M | — |
| 2023 | 2023-12-31 | −$193.2M | −$141.9M | — |
| 2022 | 2022-12-31 | −$51.3M | $118.8M | — |
| 2021 | 2021-12-31 | −$170.1M | −$2.8M | — |
| 2020 | 2020-12-31 | −$167.3M | −$109.5M | — |
| 2019 | 2019-12-31 | −$57.8M | — | — |
Tarsus Pharmaceuticals quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$115.8M | −$91.6M | — |
| Q1 2026 | 2026-03-31 | −$13.5M | $89.9M | — |
| Q4 2025 | 2025-12-31 | −$100.6M | −$78.2M | — |
| Q3 2025 | 2025-09-30 | −$30.2M | $72.4M | — |
| Q2 2025 | 2025-06-30 | −$24.2M | $83.3M | — |
| Q1 2025 | 2025-03-31 | −$103.4M | $58.2M | — |
| Q4 2024 | 2024-12-31 | −$22.4M | $170.8M | — |
| Q3 2024 | 2024-09-30 | −$102.6M | $92.2M | — |
| Q2 2024 | 2024-06-30 | −$107.5M | −$27.5M | — |
| Q1 2024 | 2024-03-31 | −$161.6M | −$120.8M | — |
| Q4 2023 | 2023-12-31 | −$193.2M | −$141.9M | — |
| Q3 2023 | 2023-09-30 | −$194.9M | −$45.5M | — |
| Q2 2023 | 2023-06-30 | −$79.9M | $145.3M | — |
| Q1 2023 | 2023-03-31 | −$40.8M | $114.0M | — |
| Q4 2022 | 2022-12-31 | −$51.3M | $118.8M | — |
| Q3 2022 | 2022-09-30 | −$149.4M | $33.1M | — |
| Q2 2022 | 2022-06-30 | −$225.2M | −$49.1M | — |
| Q1 2022 | 2022-03-31 | −$154.8M | $732,000 | — |
| Q4 2021 | 2021-12-31 | −$170.1M | −$2.8M | — |
| Q3 2021 | 2021-09-30 | −$182.5M | −$97.0M | — |
| Q2 2021 | 2021-06-30 | −$176.1M | — | — |
| Q1 2021 | 2021-03-31 | −$155.5M | — | — |
| Q4 2020 | 2020-12-31 | −$167.3M | −$109.5M | — |
| Q3 2020 | 2020-09-30 | −$85.5M | — | — |
| Q4 2019 | 2019-12-31 | −$57.8M | — | — |
Tarsus Pharmaceuticals net debt trends
Over the last five fiscal years, Tarsus Pharmaceuticals's net debt increased from −$167.3M to −$100.6M, a change of $66.7M. The latest reported quarter, Q2 2026, shows −$115.8M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗